Payment overview · 2025
General Payments
$96.43
5 reported records · 4 companies
Healthcare provider profile · identity verified
Waseem Hussain, MD
Allopathic & Osteopathic Physicians|Family Medicine · LANHAM, MD · NPI 1093809295
Verified facts
What the public records show
CMS Open Payments records show Waseem Hussain, MD received $96.43 in general payments during 2025 across 5 reported records.
PFIZER INC. accounted for 33.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 9 associated products.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 73 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 93 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| PFIZER INC. | Unresolved — no canonical attribution shown | $31.90 | 33.1% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $24.48 | 25.4% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $23.30 | 24.2% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $16.75 | 17.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $96.43 | 5 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $24.48 | 1 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $23.30 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $17.77 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $17.77 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $17.77 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $16.75 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $16.75 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $14.13 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $14.13 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
73 | 15 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
93 | 31 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 851 | 288 |
| Amlodipine Besylate | Amlodipine Besylate | 569 | 196 |
| Metoprolol Succinate | Metoprolol Succinate | 319 | 104 |
| Levothyroxine Sodium | Levothyroxine Sodium | 285 | 90 |
| Losartan Potassium | Losartan Potassium | 212 | 77 |
| Metformin Hcl | Metformin Hcl | 211 | 82 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 187 | 72 |
| Alendronate Sodium | Alendronate Sodium | 168 | 55 |
| Pravastatin Sodium | Pravastatin Sodium | 161 | 58 |
| Pantoprazole Sodium | Pantoprazole Sodium | 158 | 69 |
| Simvastatin | Simvastatin | 145 | 43 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 135 | 47 |
| Hydrochlorothiazide | Hydrochlorothiazide | 135 | 51 |
| Lisinopril | Lisinopril | 134 | 46 |
| Jardiance | Empagliflozin | 118 | 40 |
| Tamsulosin Hcl | Tamsulosin Hcl | 115 | 45 |
| Carvedilol | Carvedilol | 102 | 36 |
| Clopidogrel | Clopidogrel Bisulfate | 97 | 31 |
| Metformin Hcl Er | Metformin Hcl | 94 | 35 |
| Eliquis | Apixaban | 93 | 31 |
| Allopurinol | Allopurinol | 87 | 28 |
| Furosemide | Furosemide | 87 | 33 |
| Fluticasone Propionate | Fluticasone Propionate | 85 | 37 |
| Omeprazole | Omeprazole | 85 | 31 |
| Montelukast Sodium | Montelukast Sodium | 83 | 24 |
| Gabapentin | Gabapentin | 82 | 33 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 78 | 28 |
| Famotidine | Famotidine | 75 | 30 |
| Ozempic | Semaglutide | 73 | 15 |
| Escitalopram Oxalate | Escitalopram Oxalate | 72 | 25 |
| Mounjaro | Tirzepatide | 72 | 15 |
| Trulicity | Dulaglutide | 66 | 15 |
| Sertraline Hcl | Sertraline Hcl | 62 | 21 |
| Indapamide | Indapamide | 61 | 19 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 61 | 18 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 59 | 19 |
| Glimepiride | Glimepiride | 58 | 16 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 58 | 32 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 57 | 19 |
| Clonidine | Clonidine | 54 | 15 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 49 | 16 |
| Azelastine Hcl | Azelastine Hcl | 48 | 22 |
| Clonazepam | Clonazepam | 48 | 14 |
| Ramipril | Ramipril | 48 | 17 |
| Bupropion Xl | Bupropion Hcl | 47 | 12 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 46 | 15 |
| Ezetimibe | Ezetimibe | 46 | 22 |
| Metoprolol Tartrate | Metoprolol Tartrate | 46 | 18 |
| Hydralazine Hcl | Hydralazine Hcl | 45 | 15 |
| Alprazolam | Alprazolam | 43 | 14 |
| Valsartan | Valsartan | 43 | 17 |
| Zolpidem Tartrate | Zolpidem Tartrate | 43 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 42 | 14 |
| Potassium Chloride | Potassium Chloride | 42 | 14 |
| Pregabalin | Pregabalin | 41 | 11 |
| Synjardy Xr | Empagliflozin/Metformin Hcl | 40 | 11 |
| Clonidine Hcl | Clonidine Hcl | 39 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 39 | 15 |
| Synthroid | Levothyroxine Sodium | 39 | 13 |
| Naproxen | Naproxen | 36 | 14 |
| Tramadol Hcl | Tramadol Hcl | 34 | suppressed |
| Synjardy | Empagliflozin/Metformin Hcl | 33 | 12 |
| Spironolactone | Spironolactone | 32 | 13 |
| Telmisartan | Telmisartan | 32 | 11 |
| Valacyclovir | Valacyclovir Hcl | 32 | 13 |
| Irbesartan | Irbesartan | 30 | 12 |
| Janumet | Sitagliptin Phos/Metformin Hcl | 30 | suppressed |
| Mirtazapine | Mirtazapine | 30 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 29 | 21 |
| Tresiba Flextouch U-200 | Insulin Degludec | 27 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 26 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 25 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 25 | suppressed |
| Nifedipine Er | Nifedipine | 25 | 11 |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 25 | 12 |
| Finasteride | Finasteride | 24 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 24 | suppressed |
| Dutasteride | Dutasteride | 23 | suppressed |
| Atenolol | Atenolol | 22 | 11 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 21 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 21 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 21 | suppressed |
| Celecoxib | Celecoxib | 20 | suppressed |
| Chlorthalidone | Chlorthalidone | 20 | suppressed |
| Ibuprofen | Ibuprofen | 20 | suppressed |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 19 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 19 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 19 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 19 | 15 |
| Verapamil Er | Verapamil Hcl | 19 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 18 | suppressed |
| Diazepam | Diazepam | 18 | suppressed |
| Januvia | Sitagliptin Phosphate | 18 | suppressed |
| Lansoprazole | Lansoprazole | 18 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 18 | suppressed |
| Levemir Flexpen | Insulin Detemir | 18 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 18 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 18 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 17 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 17 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 17 | 11 |
| Xarelto | Rivaroxaban | 17 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 16 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 16 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 16 | suppressed |
| Prednisone | Prednisone | 16 | suppressed |
| Amoxicillin | Amoxicillin | 15 | 13 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 15 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 15 | suppressed |
| Levetiracetam | Levetiracetam | 15 | suppressed |
| Silodosin | Silodosin | 15 | suppressed |
| Nystatin | Nystatin | 14 | suppressed |
| Olanzapine | Olanzapine | 14 | suppressed |
| Spironolactone-Hctz | Spironolact/Hydrochlorothiazid | 14 | suppressed |
| Tradjenta | Linagliptin | 14 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 14 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 14 | suppressed |
| Estradiol | Estradiol | 13 | suppressed |
| Klor-Con M20 | Potassium Chloride | 13 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 13 | suppressed |
| Meloxicam | Meloxicam | 13 | suppressed |
| Trandolapril | Trandolapril | 13 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 12 | suppressed |
| Linzess | Linaclotide | 12 | suppressed |
| Myrbetriq | Mirabegron | 12 | suppressed |
| Risedronate Sodium | Risedronate Sodium | 12 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 12 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 12 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 12 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 12 | suppressed |
| Azelastine-Fluticasone | Azelastine/Fluticasone | 11 | suppressed |
| Cephalexin | Cephalexin | 11 | suppressed |
| Ciclopirox | Ciclopirox Olamine | 11 | suppressed |
| Edarbi | Azilsartan Medoxomil | 11 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 11 | suppressed |
| Insulin Aspart Prot Mix 70-30 | Insulin Aspart Prot/Insuln Asp | 11 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 11 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 11 | suppressed |
| Roflumilast | Roflumilast | 11 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $96.43 · 5 records | PFIZER INC. | ABRYSVO, COMIRNATY, LEQVIO, NURTEC ODT, OTEZLA, PREVNAR 20, REPATHA, Wegovy, ZAVZPRET | 2 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with Novo Nordisk Inc?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error